This month marks the one-year anniversary of our Medicines We Can Trust campaign. To commemorate our first campaign milestone, below you’ll see a snapshot of progress over the last year, including a social media toolkit that we hope you’ll share on your channels.
Evolution of Rifampin resistance in Escherichia coli and Mycobacterium smegmatis due to substandard drugs
Poor-quality medicines undermine the treatment of infectious diseases, such as tuberculosis, which require months of treatment with rifampin and other drugs.
This Thursday (25 April) is World Malaria Day and we hope you’ll join us in calling for #MedsWeCanTrust. If you or your organization would be willing to share social media content on this topic, please see our #WorldMalariaDay social media toolkit for suggested language and graphics.
Every person has the right to expect that when they use a medical product, whether medicine, vaccine or diagnostic kit, it works. But too often, that is not the case. Substandard medical products result from errors, negligence or poor practice in manufacturing, transportation and/or storage.
Pharmaceutical quality assurance of local private distributors: a secondary analysis in 13 low-and middle-income countries
The rapid globalisation of the pharmaceutical production and distribution has not been supported by harmonisation of regulatory systems worldwide. Thus, the supply systems in low-income and middle-income countries (LMICs) remain exposed to the risk of poor-quality medicines. To contribute to estimating this risk in the private sector in LMICs, we assessed the quality assurance system of a convenient sample of local private pharmaceutical distributors.
During this month’s United Nations General Assembly (UNGA), countries will host the first-ever High-Level Meeting on Universal Health Coverage (UHC), where they will issue a political declaration to accelerate progress toward health for all by 2030.
Artemisinin-based combination therapies are the frontline treatment of Plasmodium falciparum malaria.
Quality assurance of medicines supplied to low income and middle-income countries: poor products in shiny boxes?
In today's context of globalisation of pharmaceutical production and distribution, international and national procurement agencies play a de facto key role in defining the quality of medicines available in sub-Saharan Africa.